Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma

NCT07226856 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07226856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single-Arm Trial of BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-Paclitaxel in the First Line Setting of Advanced Pancreatic Adenocarcinoma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2025
Completion date
February 28, 2028
Enrollment
43 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma, recurrent pancreatic adenocarcinoma, stage iv pancreatic cancer ajcc v8